Somewhat Favorable News Coverage Somewhat Unlikely to Affect Five Prime Therapeutics (FPRX) Stock Price

News articles about Five Prime Therapeutics (NASDAQ:FPRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.4006385997759 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Five Prime Therapeutics (FPRX) traded down $0.20 during trading on Friday, hitting $25.56. 407,092 shares of the stock traded hands, compared to its average volume of 405,875. Five Prime Therapeutics has a 12-month low of $21.41 and a 12-month high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). The company had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.72) EPS. sell-side analysts expect that Five Prime Therapeutics will post -5.56 earnings per share for the current year.

Several research analysts have commented on FPRX shares. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 price target (down from $55.00) on shares of Five Prime Therapeutics in a report on Thursday, August 10th. Royal Bank Of Canada reissued a “buy” rating and issued a $41.00 price target on shares of Five Prime Therapeutics in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target for the company in a report on Monday, October 16th. BMO Capital Markets restated a “hold” rating and set a $39.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Finally, ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $64.00.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/11/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-five-prime-therapeutics-fprx-stock-price.html.

In related news, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now owns 2,000 shares in the company, valued at approximately $76,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total transaction of $27,198.00. Following the completion of the transaction, the director now owns 600 shares in the company, valued at approximately $27,198. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,400 shares of company stock worth $175,666. Corporate insiders own 6.50% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply